Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)

This study is using artificial intelligence (AI) and radiomics — detailed pattern analysis of CT and MRI scan images — to predict how well liver cancer (hepatocellular carcinoma) patients will respond to immunotherapy and how long they will survive. The aim is to improve treatment planning using imaging data. **You may be eligible if...** - You were treated for hepatocellular carcinoma (liver cancer) at Wuhan Union Hospital between July 2025 and July 2026 - You are 18 years of age or older - You had at least one CT or MRI scan before starting treatment - Your liver cancer diagnosis was confirmed by a tissue biopsy **You may NOT be eligible if...** - Your scan images are of poor quality - Your medical records are incomplete or you were lost to follow-up - You have a second primary cancer (a separate unrelated cancer) - You are not a liver cancer patient treated at the specified hospital during the specified period Talk to your doctor to see if this trial is right for you.